Halozyme announces temporary halt of Phase 2 trial enrollment for PEGPH20 Halozyme announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee, it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer. The DMC is assessing clinical data that indicates a possible difference in the thromboembolic event rate between the group of patients treated with PEGPH20, nab-paclitaxel and gemcitabine versus the group of patients treated with nab-paclitaxel and gemcitabine without PEGPH20. The company is halting enrollment and dosing of PEGPH20 as precautionary actions while the DMC's full evaluation of the data is ongoing.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: Acadia (ACHC) initiated with an Overweight at KeyBanc... Altisource Residential (RESI) initiated with a Neutral at Nomura... Colony Starwood Homes (SFR) initiated with a Buy at Nomura... EyeGate (EYEG) initiated with a Buy at Rodman & Renshaw... Fortinet (FTNT) initiated with an Outperform at Northland... Halozyme (HALO) initiated with a Buy at Canaccord... Lendingtree (TREE) initiated with an Outperform at Northland... Lindblad Expeditions (LIND) initiated with an Outperform at Credit Suisse... Summit Therapeutics (SMMT) initiated with a Buy at Canaccord... VolitionRx (VNRX) initiated with a Buy at Rodman & Renshaw.